Neopharm, Prima BioMed deal

Prima entered into a binding term sheet to grant Neopharm an exclusive license to market Prima's CVac in Israel and the Palestinian Authority. The companies expect to enter a final deal within 90 days

Read the full 346 word article

How to gain access

Continue reading with a
two-week free trial.